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ACE inhibitor benefits patients 
with advanced kidney disease
Angiotensin-converting enzyme (ACE) inhibitors have been 
found to provide renal protection in patients with mild to 
moderate renal insuffi  ciency (serum creatinine ≤3.0 mg/dl), 
but many physicians are reluctant to use them in patients 
with advanced renal insuffi  ciency because of concerns 
with hyperkalemia and worsening renal insuffi  ciency. To 
test whether these concerns are justifi ed, researchers from 
Nanfang Hospital in Guangzhou, China, randomly assigned 
104 patients with serum creatinine levels of 1.5–3.0 mg/dl 
(group 1) to receive 20 mg benazepril per day, and 224 
with serum creatinine levels of 3.1–5.0 mg/dl (group 2) to 
receive 20 mg benazepril per day or placebo, aft er an 8-week 
run-in period. All patients also received conventional 
antihypertensive treatment. During the next 3.4 years, 41% 
of group 2 patients receiving benazepril, and 60% of those 
receiving placebo, reached the primary composite end point 
of a doubling of serum creatinine level or the presence of 
end-stage renal disease or death — a 43% reduction with the 
ACE inhibitor. Primary end point events occurred in 22% of 
group 1. Benazepril therapy was also associated with a 52% 
reduction in the level of proteinuria, and a 23% reduction 
in the rate of decline of renal function. Th us, benazepril 
provided renal protection in patients with advanced non-
diabetic renal insuffi  ciency. In an editorial accompanying the 
study, Lee Hebert said the results suggest that it is worthwhile 
to continue ACE inhibitors in patients with chronic kidney 
disease even when the serum creatinine level continues to 
climb. (N Engl J Med 2006; 354: 131–140)
Jai Radhakrishnan
Another cause of dominant 
polycystic kidney disease is a 
ciliary protein
Oral–facial–digital syndrome type 1 (Ofd1) is an X-linked 
dominant (male lethal) developmental anomaly associated 
with digital malformation, facial anomalies, and polycystic 
kidney disease. In a new study, Ferrante et al. generated 
mice lacking Ofd1. Th ey reproduced many prior clinical 
fi ndings, albeit to a more severe degree, perhaps because 
of diff erences in X chromosome inactivation between 
mice and humans. Remarkably, there was left –right axis 
symmetry defects in the mice. On examination of the node, 
the site of generation of the fi rst left –right asymmetry, 
they found absence of cilia. Further examination of renal 
tubular epithelial cells in heterozygous females also showed 
absence of cilia. Th e protein was found in the centrosome 
and basal body of ciliated cells. Hence, this disease can now 
be added to the group of ciliary diseases that cause, among 
other anomalies, cysts in the kidney and abnormal left –right 
asymmetry. (Nat Genet 2006; 38: 112–117)
Qais Al-Awqati
Pharmacological manipulation of 
HIF
Many human diseases, including some forms of acute renal 
failure and renal artery stenosis, are characterized by the 
development of tissue hypoxia. Inadequate oxygenation 
can cause cellular dysfunction and death. Tissues use many 
strategies, including induction of angiogenesis and alterations 
in metabolism, to survive under hypoxic conditions. Th e 
heterodimeric transcription factor hypoxia-inducible factor 
(HIF) is a master regulator of genes that promote adaptation 
to hypoxia. HIF activity is linked to oxygen availability, as 
members of the egg laying-defective-nine (EGLN) family 
hydroxylate HIFα subunits on specifi c prolyl residues when 
oxygen is present, which marks them for ubiquitination and 
proteasomal degradation. Safran et al. created a mouse that 
ubiquitously expresses a bioluminescent reporter consisting 
of fi refl y luciferase fused to a region of HIF that is suffi  cient 
for oxygen-dependent degradation. In validation studies, they 
showed that this mouse is useful for monitoring hypoxic tissues 
and evaluating therapeutic agents that stabilize HIF. One such 
agent, the HIF prolyl hydroxylase inhibitor FG-4383, was 
active in the liver and kidney aft er systemic administration, 
as determined by bioluminescence imaging, transcription 
profi ling, and production of erythropoietin. Th is indicates that 
the HIF transcriptional program can be manipulated in vivo 
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with orally active organic small molecules. (Proc Natl Acad Sci 
USA 2006; 103: 105–110)
Juan Oliver
Growth factor midkine and 
diabetic nephropathy
Growth factors have been implicated as being among the many 
contributors to the development of diabetic glomerulosclerosis. 
Kosugi et al. recently evaluated the potential role of the growth 
factor midkine (MdK) in experimental diabetic glomerular 
changes. Using the streptozotocin-induced model of diabetes, 
they reported that mice defi cient in midkine (MdK–/–) 
exhibited strikingly milder nephropathy than MdK+/+ 
mice, even though both mice showed similar amounts of 
hyperglycemia. MdK expression was induced in the glomerular 
mesangium of MdK+/+ mice with diabetic nephropathy 
and in primary cultured mesangial cells exposed to high 
glucose loading. Mesangial cells cultured from MdK–/– mice 
exhibited reduced phosphorylation of protein kinase C and 
extracellular signal-regulated kinase, as well as reduced 
production of transforming growth factor-β1. Th e addition 
of exogenous MdK restored extracellular signal-regulated 
kinase phosphorylation in MdK–/– cells under high-glucose 
conditions, whereas an MdK antisense oligodeoxynucleotide 
suppressed MdK in MdK+/+ cells. Th e authors propose that 
MdK may rank among key molecules in diabetic glomerular 
nephropathy and suggest that MdK accelerates the intracellular 
signaling network evoked by hyperglycemia. (Am J Pathol 
2006; 168: 9–19)
Detlef Schlöndorﬀ 
Cell epitope mimicry in anti-
glomerular basement membrane 
disease
For a long time, the possibility has been discussed that 
epitope mimicry between infectious agents and endogenous 
proteins may be a cause of postinfectious glomerulonephritis. 
Arends et al. now reexamine the possibility that T-cell epitope 
mimicry may exist in anti-glomerular basement membrane 
(anti-GBM) disease. Although collagen 4α3 NCI (Col4α3 
NCI) has been identifi ed as the responsible autoantigen, it 
remains unknown how autoimmunity to this autoantigen 
is provoked. Arends et al. have demonstrated in a rat model 
that a single nephritogenic T-cell epitope, pCol28–40, of 
Col4α3 NCI induces glomerulonephritis. Th ey hypothesized 
that microbial peptides that mimic this T-cell epitope could 
induce the disease. Based on the critical residue motif 
(xxTxNPsxx) of pCol28–40, seven peptides derived from 
human infection-related microbes were chosen through a 
GenBank search and synthesized. All seven peptides showed 
crossreactivity with pCol28–40-specifi c T cells at various 
levels. Four peptides induced transient proteinuria and minor 
glomerular injury in experimental animals. However, the 
other three peptides induced severe proteinuria and modest 
to severe glomerulonephritis in 16–25% of the immunized 
rats. Unexpectedly, the most nephritogenic peptide, pCB, 
derived from Clostridium botulinum, also induced modest  to 
severe pulmonary hemorrhage, another important feature of 
anti-GBM disease; this was not correlated with the severity 
of glomerulonephritis. Th is fi nding suggests that subtle 
variations in T-cell epitope mimicry specifi city may lead 
to diff erent clinical manifestations of anti-GBM disease. In 
summary, these studies raise the possibility that a single T-cell 
epitope mimicry by microbial antigens may be suffi  cient to 
induce anti-GBM disease; thus they rekindle the debate of 
infectious agent mimicry in the pathogenesis of some forms of 
glomerulonephritis. (J Immunol 2006; 176: 1252–1258)
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